| 108268-4 | Housing characteristics | CLIN |
| 108269-2 | Access to electricity (qualitative) | CLIN |
| 10827-4 | Reticulum.microscopic observation (Tissue, gomori stain) | PATH |
| 108270-0 | Residence structural barrier | CLIN |
| 108271-8 | Housing condition | CLIN |
| 108272-6 | Household expenditure | CLIN |
| 108273-4 | Preventive medicine screening level | CLIN |
| 108274-2 | Preventive medicine screening reminder letter | DOC.ONTOLOGY |
| 108275-9 | Warranty coverage information | DOC.ONTOLOGY |
| 108276-7 | Screening invitation letter | DOC.ONTOLOGY |
| 108277-5 | Implanted device note | DOC.ONTOLOGY |
| 108279-1 | cycloSPORINE (Blood, lc/ms/ms) | DRUG/TOX |
| 10828-2 | Urate crystals.microscopic observation (Tissue, de galantha stain) | PATH |
| 108281-7 | Pregabalin (oral fluid) (Saliva, qualitative) | DRUG/TOX |
| 108282-5 | 7-Aminoclonazepam (oral fluid) (Saliva) | DRUG/TOX |
| 108283-3 | Phentermine (oral fluid) (Saliva, qualitative) | DRUG/TOX |
| 108284-1 | Gabapentin (oral fluid) (Saliva, qualitative) | DRUG/TOX |
| 108285-8 | Pyruvate kinase M2 | CHEM |
| 108286-6 | LDL receptor related protein 4 Ab | SERO |
| 108287-4 | Reticulocyte - RBC Hemoglobin | HEM/BC |
| 108288-2 | Endomysium IgM Ab | SERO |
| 108289-0 | Yeast susceptibility limited panel - Isolate (minimum inhibitory concentration (mic)) | PANEL.UA |
| 10829-0 | Silicon | DRUG/TOX |
| 108290-8 | Outcome and assessment information set (OASIS) form - version E2 during assessment period | PANEL.SURVEY.CMS |
| 108291-6 | Outcome and assessment information set (OASIS) form - version E2 - Start of Care during assessment period | PANEL.SURVEY.CMS |
| 108292-4 | Outcome and assessment information set (OASIS) form - version E2 - Resumption of Care during assessment period | PANEL.SURVEY.CMS |
| 108293-2 | OASIS E2 - DC during assessment period | PANEL.SURVEY.CMS |
| 108294-0 | OASIS E2 - TRN during assessment period | PANEL.SURVEY.CMS |
| 108295-7 | Outcome and assessment information set (OASIS) form - version E2 - Death at Home during assessment period | PANEL.SURVEY.CMS |
| 108296-5 | Outcome and assessment information set (OASIS) form - version E2 - Follow Up during assessment period | PANEL.SURVEY.CMS |
| 108297-3 | Trimeperidine (Urine) | LABORDERS.ONTOLOGY |
| 108298-1 | Trimipramine (Urine) | LABORDERS.ONTOLOGY |
| 1083-5 | Js sup(a) Ag on Red Blood Cells from Donor (qualitative) | BLDBK |
| 10830-8 | Surgical operation note complications | H&P.SURG PROC |
| 108300-5 | Vanillylmandelate/Creatine (Urine) | LABORDERS.ONTOLOGY |
| 108301-3 | Vilazodone (Urine) | LABORDERS.ONTOLOGY |
| 108302-1 | Vortioxetine (Urine) | LABORDERS.ONTOLOGY |
| 108303-9 | Warfarin (Urine) | LABORDERS.ONTOLOGY |
| 108305-4 | Xanthine (Urine) | LABORDERS.ONTOLOGY |
| 10831-6 | Surgical operation note complications | H&P.SURG PROC |
| 108315-3 | Chlamydia trachomatis Ag sediment (Urine) | LABORDERS.ONTOLOGY |
| 10832-4 | Glucose --15 minutes post 50 g lactose PO | CHAL |
| 108326-0 | Atopobium vaginae DNA in Vaginal fluid | LABORDERS.ONTOLOGY |
| 108327-8 | Brucella sp Ag in Vaginal fluid | LABORDERS.ONTOLOGY |
| 108328-6 | Candida sp DNA in Vaginal fluid | LABORDERS.ONTOLOGY |
| 108329-4 | Chlamydia trachomatis Ag in Vaginal fluid | LABORDERS.ONTOLOGY |
| 10833-2 | Insulin --7 hours post 75 g glucose PO | CHAL |
| 108337-7 | Beta-N-acetylhexosaminidase in Leukocytes | LABORDERS.ONTOLOGY |
| 108338-5 | Beta-N-acetylhexosaminidase.A in Leukocytes | LABORDERS.ONTOLOGY |
| 108339-3 | Cerebroside sulfatase in Leukocytes | LABORDERS.ONTOLOGY |